Advances in precision medicine are reshaping the management of gynecologic cancers, with molecular profiling, biomarker-guided treatment selection, targeted ...
Safety featured universal TEAEs and 92% grade ≥3 events; anemia (39.5%) predominated, discontinuations were frequent, and ...
New real-world data from the 1INSPIRE study shows that frontline niraparib (Zejula) maintenance is well-tolerated in patients ...
Mirvetuximab soravtansine shows 16.4-month OS in ovarian cancer, though poor ECOG status and toxicity significantly impact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results